These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 38542088)

  • 21. Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease.
    Beldhuis IE; Lam CSP; Testani JM; Voors AA; Van Spall HGC; Ter Maaten JM; Damman K
    Circulation; 2022 Mar; 145(9):693-712. PubMed ID: 35226558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An evidence-based review of recent advances in therapy for heart failure with reduced ejection fraction (HFrEF).
    Raj L; Adhyaru B
    Postgrad Med J; 2016 Dec; 92(1094):726-734. PubMed ID: 27708003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in the Management of Heart Failure with Reduced Ejection Fraction; The Role of SGLT2is, ARNI, Myotropes, Vericiguat, and Anti-inflammatory Agents: A Mini-review.
    Vrachatis DA; Papathanasiou KA; Giotaki SG; Raisakis K; Kaoukis A; Kossyvakis C; Theodorakis A; Pediotidis S; Avramides D; Siasos G; Deftereos S
    Curr Pharm Des; 2023; 29(7):509-518. PubMed ID: 36927423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
    Martin N; Manoharan K; Davies C; Lumbers RT
    Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Consensus statement on the current pharmacological prevention and management of heart failure.
    Sindone AP; De Pasquale C; Amerena J; Burdeniuk C; Chan A; Coats A; Hare DL; Macdonald P; Sverdlov A; Atherton JJ
    Med J Aust; 2022 Aug; 217(4):212-217. PubMed ID: 35908234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention?
    Abdelhamid M; Rosano G; Metra M; Adamopoulos S; Böhm M; Chioncel O; Filippatos G; Jankowska EA; Lopatin Y; Lund L; Milicic D; Moura B; Ben Gal T; Ristic A; Rakisheva A; Savarese G; Mullens W; Piepoli M; Bayes-Genis A; Thum T; Anker SD; Seferovic P; Coats AJS
    Eur J Heart Fail; 2022 Sep; 24(9):1460-1466. PubMed ID: 35753058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of Quality of Care for US Veterans With Recent-Onset Heart Failure With Reduced Ejection Fraction.
    Sandhu AT; Kohsaka S; Turakhia MP; Lewis EF; Heidenreich PA
    JAMA Cardiol; 2022 Feb; 7(2):130-139. PubMed ID: 34757380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry.
    Khazanie P; Liang L; Curtis LH; Butler J; Eapen ZJ; Heidenreich PA; Bhatt DL; Peterson ED; Yancy CW; Fonarow GC; Hernandez AF
    Circ Heart Fail; 2016 Feb; 9(2):e002444. PubMed ID: 26867758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Guideline-Directed Medical Therapy in Newly Diagnosed Heart Failure With Reduced Ejection Fraction in the Community.
    Dunlay SM; Killian JM; Roger VL; Schulte PJ; Blecker SB; Savitz ST; Redfield MM
    J Card Fail; 2022 Oct; 28(10):1500-1508. PubMed ID: 35902033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial.
    Lewis GD; Voors AA; Cohen-Solal A; Metra M; Whellan DJ; Ezekowitz JA; Böhm M; Teerlink JR; Docherty KF; Lopes RD; Divanji PH; Heitner SB; Kupfer S; Malik FI; Meng L; Wohltman A; Felker GM
    JAMA; 2022 Jul; 328(3):259-269. PubMed ID: 35852527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Implications of Functional Mitral Regurgitation Severity in Patients with Heart Failure with Reduced Ejection Fraction (HFrEF).
    Naser N
    Med Arch; 2022 Feb; 76(1):17-22. PubMed ID: 35422569
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of hydralazine-isosorbide dinitrate combination in African American and other race/ethnic group patients with heart failure and reduced left ventricular ejection fraction.
    Golwala HB; Thadani U; Liang L; Stavrakis S; Butler J; Yancy CW; Bhatt DL; Hernandez AF; Fonarow GC
    J Am Heart Assoc; 2013 Aug; 2(4):e000214. PubMed ID: 23966379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT.
    Cohn JN; Tam SW; Anand IS; Taylor AL; Sabolinski ML; Worcel M;
    J Card Fail; 2007 Jun; 13(5):331-9. PubMed ID: 17602978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heart Failure With Recovered Ejection Fraction in African Americans: Results From the African-American Heart Failure Trial.
    Chang KW; Beri N; Nguyen NH; Arbit B; Fox S; Mojaver S; Clopton P; Tam SW; Taylor AL; Cohn JN; Maisel AS; Anand IS
    J Card Fail; 2018 May; 24(5):303-309. PubMed ID: 28918108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 2020 Heart Failure Society of South Africa perspective on the 2016 European Society of Cardiology Chronic Heart Failure Guidelines.
    Hitzeroth J; Mpe M; Klug E; Ranjith N; Sliwa K; Steingo L; Lachman L; Tsabedze N; Ntusi NAB; Society Of South Africa HF
    S Afr Med J; 2020 Aug; 110(8b):13057. PubMed ID: 32880257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of new medical therapies in patients with heart failure, reduced ejection fraction, and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis.
    Ameri P; De Marzo V; Zoccai GB; Tricarico L; Correale M; Brunetti ND; Canepa M; De Ferrari GM; Castagno D; Porto I
    Eur Heart J Cardiovasc Pharmacother; 2022 Dec; 8(8):768-776. PubMed ID: 34928347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Where are we in 2021 with heart failure with reduced ejection fraction?-current outlook and expectations from new promising clinical trials.
    Dębska-Kozłowska A; Książczyk M; Lelonek M
    Heart Fail Rev; 2022 Mar; 27(2):419-430. PubMed ID: 34050489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medical therapy following hospitalization for heart failure with reduced ejection fraction and association with discharge to long-term care: a cross-sectional analysis of the REasons for Geographic And Racial Differences in Stroke (REGARDS) population.
    Levitan EB; Van Dyke MK; Chen L; Durant RW; Brown TM; Rhodes JD; Olubowale O; Adegbala OM; Kilgore ML; Blackburn J; Albright KC; Safford MM
    BMC Cardiovasc Disord; 2017 Sep; 17(1):249. PubMed ID: 28915854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacotherapy of heart failure A.D. 2023. Expert opinion of Working Group on Cardiovascular Pharmacotherapy, Polish Cardiac Society.
    Kasprzak JD; Gorczyca-Głowacka I; Sobczak-Kaleta M; Barylski M; Drożdż J; Filipiak KJ; Kapłon-Cieślicka A; Lelonek M; Mamcarz A; Ochijewicz D; Ryś-Czaporowska A; Starzyk K; Szymański FM; Wełnicki M; Wożakowska-Kapłon B
    Kardiol Pol; 2023; 81(5):537-556. PubMed ID: 37179465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment?
    Ameri P; Bertero E; Maack C; Teerlink JR; Rosano G; Metra M
    Eur Heart J Cardiovasc Pharmacother; 2021 Nov; 7(6):539-546. PubMed ID: 34037742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.